<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To further elucidate the pathogenetic role of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E (Apo E) in <z:e sem="disease" ids="C0154671" disease_type="Disease or Syndrome" abbrv="">degenerative brain disorders</z:e>, we analyzed cerebrospinal fluid (CSF) levels of Apo E in 85-year-old subjects with <z:hpo ids='HP_0000726'>dementia</z:hpo> disorders </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Survey </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: Community </plain></SENT>
<SENT sid="3" pm="."><plain>PARTICIPANTS: Population-based sample of 27 demented (12 with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> [AD]; 13, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> [VAD]; and 2, other types of <z:hpo ids='HP_0000726'>dementia</z:hpo>) and 35 nondemented individuals </plain></SENT>
<SENT sid="4" pm="."><plain>MAIN OUTCOME MEASURES: Cerebrospinal fluid levels of Apo E, Apo E polymorphism, and brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> and white matter lesions (WMLs) measured by computed tomography (CT) of the brain </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000726'>Dementia</z:hpo> was defined according to Diagnostic and Statistical Manual of <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">Mental Disorders</z:e>, Third Edition, Revised criteria; AD, National Institute of Neurological and <z:e sem="disease" ids="C0009460" disease_type="Mental or Behavioral Dysfunction" abbrv="">Communicative Disorders</z:e> and <z:hpo ids='HP_0001297'>Stroke</z:hpo> and the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> and Related Disorders Association criteria; and VAD, National Institute of <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">Neurological Disorders</z:e> and <z:hpo ids='HP_0001297'>Stroke</z:hpo> and the Association Internationale pour la Recherche et l'Enseignement en Neuroscience criteria </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The mean (+/- SD) CSF levels of Apo E were lower in the AD (2.6 +/- 1.5 mg/L; P &lt; .02) and VAD groups (2.5 +/- 0.9 mg/L; P &lt; .002) than in the nondemented group (3.8 +/- 1.7 mg/L) </plain></SENT>
<SENT sid="7" pm="."><plain>Cerebrospinal fluid levels of Apo E decreased with increasing severity of <z:hpo ids='HP_0000726'>dementia</z:hpo> and with increasing temporal cortical and central frontal <z:mpath ids='MPATH_127'>atrophy</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>In nondemented individuals, CSF levels of Apo E decreased with increasing degree of WMLs </plain></SENT>
<SENT sid="9" pm="."><plain>Cerebrospinal fluid levels of Apo E were not influenced by the Apo E4 isoform </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Whether our finding of an association between low CSF levels of Apo E and <z:hpo ids='HP_0000726'>dementia</z:hpo> disorders (both degenerative, such as AD, and vascular, such as VAD) is related to the pathogenesis of these disorders or is a secondary consequence of the disease process remains to be established </plain></SENT>
<SENT sid="11" pm="."><plain>Although statistical correlations do not give direct evidence of causal relations, the correlations between CSF level of Apo E and severity of <z:hpo ids='HP_0000726'>dementia</z:hpo> and <z:hpo ids='HP_0002120'>cortical atrophy</z:hpo> suggest that CSF level of Apo E follows the disease process </plain></SENT>
</text></document>